SION vs VRTX
SION: A clinical-stage biotech pioneering the first drugs to directly stabilize CFTR's NBD1 domain, tackling the "undruggable" target in cystic fibrosis. VRTX: Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and groundbreaking gene-editing therapies for blood disorders and pain.
Side-by-side fundamentals
| Metric | SION | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $45.03 | $472.57 | |
| Market cap as of 2026-07-23 | $2.1B | $121.4B | |
| P/E as of 2026-07-23 | n/a | 27.98 | |
| PEG as of 2026-07-23 | -0.90 | 2.31 | SION lower |
| Net margin as of 2026-07-23 | n/a | +35.5% | |
| Gross margin as of 2026-07-23 | n/a | +86.2% | |
| Operating margin as of 2026-07-23 | n/a | +38.3% | |
| ROE as of 2026-07-23 | -27.3% | +23.9% | VRTX higher |
| ROA as of 2026-07-23 | -25.9% | +17.2% | VRTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.01 | SION lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +10.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +10.4% | |
| Beta as of 2026-07-23 | 1.40 | 0.30 | |
| 1-year return as of 2026-07-22 close | +170.7% | +0.5% | SION higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.